"Hurdles race for CAR T-cell therapy in digestive tract cancer".

Kronig, Marie-Noelle; Wehrli, Marc; Salas-Benito, Diego; Maus, Marcela V (2023). "Hurdles race for CAR T-cell therapy in digestive tract cancer". Immunological reviews, 320(1), pp. 100-119. Wiley 10.1111/imr.13273

Text Immunological_Reviews_-_2023_-_Kronig.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (2MB)

Digestive tract cancers (DTC) belong to the most investigated family of tumors. The incidence, prevalence, and mortality rate of DTC remain high, especially for patients with pancreatic cancer. Even though immunotherapy such as immune checkpoint inhibitors (ICI) have revolutionized the treatment of solid cancer types, ICI are still restricted to a very small group of patients and seem to be more efficacious in combination with chemotherapy. Cellular immunotherapy such as CAR T-cell therapy has entered clinical routine in hematological malignancies with outstanding results. There is growing interest on translating this kind of immunotherapy and success into patients with solid malignancies, such as DTC. This review attempts to describe the major advances in preclinical and clinical research with CAR T cells in DTC, considering the most relevant hurdles in each subtype of DTC.

Interest & Impact

Downloads

1 since deposited on 14 Sep 2023
1 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item